Phenotype
|
Conditions
|
Figures
|
adrenal gland development process quality, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 2
from Chou et al., 2014
|
adrenal gland development process quality, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 2
from Chou et al., 2014
|
angiogenesis increased occurrence, abnormal
|
chemical treatment by injection: trehalose 6,6'-dimycolate
|
Fig. 2 ,
Fig. 4,
Fig. S3
from Walton et al., 2018
|
angiogenesis increased occurrence, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 1
from Walton et al., 2018
|
angiogenesis increased occurrence, ameliorated
|
chemical treatment by injection: trehalose 6,6'-dimycolate, chemical treatment by environment: pazopanib
|
Fig. 4
from Walton et al., 2018
|
aortic arch diameter, normal
|
chemical treatment: semaxanib
|
Fig. 2
from Herzog et al., 2009
|
atrioventricular canal endocardium morphology, normal
|
control
|
Fig. 2
from Chen et al., 2013
|
atrioventricular canal endocardium cell normal amount, normal
|
control
|
Fig. 2
from Chen et al., 2013
|
atrioventricular valve development process quality, normal
|
control
|
Fig. 2
from Chen et al., 2013
|
blood glucose increased amount, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 1
from Carnovali et al., 2016
|
blood island atoh8 expression decreased distribution, abnormal
|
chemical treatment: bone morphogenetic protein receptor antagonist
|
Fig. 3
from Place et al., 2017
|
blood vasculature decreased branchiness, abnormal
|
chemical treatment by environment: SB 203580
|
Fig. S2
from Zhang et al., 2017
|
blood vasculature decreased branchiness, abnormal
|
chemical treatment by environment: sirolimus
|
Fig. S2
from Zhang et al., 2017
|
blood vasculature decreased branchiness, abnormal
|
chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester
|
Fig. S2
from Zhang et al., 2017
|
blood vasculature EGFP expression decreased distribution, abnormal
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vasculature morphology, abnormal
|
chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester
|
Fig. S2
from Zhang et al., 2017
|
blood vasculature morphology, abnormal
|
chemical treatment by environment: sirolimus
|
Fig. S2
from Zhang et al., 2017
|
blood vasculature morphology, abnormal
|
chemical treatment by environment: SB 203580
|
Fig. S2
from Zhang et al., 2017
|
blood vasculature EGFP expression spatial pattern, abnormal
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
blood vessel endothelial cell normal amount, normal
|
standard conditions
|
Fig. 3
from Jin et al., 2017
|
blood vessel remodeling disrupted, abnormal
|
chemical treatment: tricaine
|
Fig. S13
from Chen et al., 2012
|
blood vessel remodeling disrupted, abnormal
|
chemical treatment: diacetylmonoxime
|
Fig. S13
from Chen et al., 2012
|
brain vasculature blood vessel endothelial cell ab1-cdh5 labeling decreased amount, abnormal
|
chemical treatment by environment: IWR-1-endo
|
Fig. 4
from Hübner et al., 2018
|
brain vasculature blood vessel endothelial cell ab1-cdh5 labeling increased amount, abnormal
|
chemical treatment by environment: IWR-1-endo
|
Fig. 4
from Hübner et al., 2018
|
brain vasculature vascular sprouts esama expression decreased amount, abnormal
|
chemical treatment by environment: IWR-1-endo
|
Fig. S4
from Hübner et al., 2018
|
caudal fin width, normal
|
microgravity
|
Fig. 2
from Xie et al., 2019
|
caudal vein absent, abnormal
|
chemical treatment by injection: clodronic acid, chemical treatment by injection: carbon black nanoparticle, chemical treatment by injection: lipid micelle
|
Fig. 5
from Campbell et al., 2018
|
caudal vein decreased length, abnormal
|
chemical treatment by injection: clodronic acid, chemical treatment by injection: carbon black nanoparticle, chemical treatment by injection: lipid micelle
|
Fig. 5
from Campbell et al., 2018
|
caudal vein length, normal
|
chemical treatment by injection: clodronic acid
|
Fig. 5
from Campbell et al., 2018
|
caudal vein morphology, normal
|
chemical treatment by injection: clodronic acid
|
Fig. 5
from Campbell et al., 2018
|
caudal vein plexus kdrl expression amount, ameliorated
|
microgravity, chemical treatment: LY294002
|
Fig. 5
from Xie et al., 2019
|
caudal vein plexus kdrl expression decreased amount, abnormal
|
chemical treatment: LY294002
|
Fig. 6
from Xie et al., 2019
|
caudal vein plexus decreased width, abnormal
|
chemical treatment: LY294002
|
Fig. 6
from Xie et al., 2019
|
caudal vein plexus kdrl expression increased amount, abnormal
|
microgravity
|
Fig. 3
from Xie et al., 2019
|
caudal vein plexus increased width, abnormal
|
microgravity
|
Fig. 3
from Xie et al., 2019
|
caudal vein plexus malformed, abnormal
|
chemical treatment by environment: nifedipine
|
Fig. 1
from Xie et al., 2018
|
caudal vein plexus malformed, abnormal
|
chemical treatment by environment: tricaine
|
Fig. 1
from Xie et al., 2018
|
caudal vein plexus morphology, normal
|
chemical treatment: DAPT
|
Fig. 3
from Chappell et al., 2013
|
caudal vein plexus width, ameliorated
|
microgravity, chemical treatment: LY294002
|
Fig. 5
from Xie et al., 2019
|
caudal vein plexus capillary amount, ameliorated
|
microgravity, chemical treatment: LY294002
|
Fig. 5
from Xie et al., 2019
|
caudal vein plexus capillary area, ameliorated
|
microgravity, chemical treatment: LY294002
|
Fig. 5
from Xie et al., 2019
|
caudal vein plexus capillary decreased amount, abnormal
|
chemical treatment: LY294002
|
Fig. 6
from Xie et al., 2019
|
caudal vein plexus capillary decreased area, abnormal
|
chemical treatment: LY294002
|
Fig. 6
from Xie et al., 2019
|
caudal vein plexus capillary increased amount, abnormal
|
microgravity
|
Fig. 3
from Xie et al., 2019
|
caudal vein plexus capillary increased area, abnormal
|
microgravity
|
Fig. 3
from Xie et al., 2019
|
caudal vein plexus sprouting angiogenesis decreased occurrence, abnormal
|
chemical treatment by environment: tricaine
|
Fig. 1
from Xie et al., 2018
|
caudal vein plexus sprouting angiogenesis decreased occurrence, abnormal
|
chemical treatment by environment: nifedipine
|
Fig. 1
from Xie et al., 2018
|
central artery decreased amount, abnormal
|
chemical treatment: IWR-1-endo
|
Fig. 3
from Vanhollebeke et al., 2015
|
central artery increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 2
from Bussmann et al., 2011
|
central artery vascular sprouts decreased amount, abnormal
|
chemical treatment by environment: IWR-1-endo
|
Fig. 1
from Hübner et al., 2018
|
cranial vasculature spatial pattern, normal
|
standard conditions
|
Fig. 6
from Liu et al., 2020
|
cranial vasculature structure, normal
|
heat exposure
|
Fig. 5
from Ton et al., 2018
|
dorsal aorta endothelial cell ab9-mapk labeling decreased amount, abnormal
|
standard conditions
|
Fig. 5
from De Angelis et al., 2017
|
dorsal aorta endothelial cell ab9-mapk labeling decreased distribution, abnormal
|
standard conditions
|
Fig. 5
from De Angelis et al., 2017
|
dorsal longitudinal anastomotic vessel malformed, abnormal
|
chemical treatment: semaxanib
|
Fig. 7
from Hassel et al., 2012
|
endothelial cell ccl38.1 expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell mia expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell tmem204 expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell lft2 expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell tmem204 expression amount, ameliorated
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell hlx1 expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell tm4sf18 expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell hmgcra expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell mfng expression amount, ameliorated
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell hlx1 expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell hlx1 expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell ccl38.1 expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell ccl38.1 expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell mia expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell mia expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell tmem204 expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell lft2 expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell lft2 expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell avpr1ab expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell avpr1ab expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell avpr1ab expression decreased amount, abnormal
|
control
|
Fig. 3
from Page et al., 2019
|
endothelial cell tm4sf18 expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell tm4sf18 expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell mfng expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell hmgcra expression decreased amount, abnormal
|
chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell mfng expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell hmgcra expression decreased amount, abnormal
|
chemical treatment: DAPT, chemical treatment: semaxanib
|
Fig. 3
from Page et al., 2019
|
endothelial cell ccl38.1 expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell tm4sf18 expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell mfng expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell mia expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell hmgcra expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell tmem204 expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell avpr1ab expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell hlx1 expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
endothelial cell vegfaa expression increased amount, abnormal
|
hypoxia
|
Figure 7
from Ki et al., 2019
|
endothelial cell lft2 expression increased amount, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Page et al., 2019
|
female organism decreased life span, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 1
from Carnovali et al., 2016
|
granuloma formation decreased occurrence, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 3
from Torraca et al., 2017
|
heart morphology, normal
|
standard conditions
|
Fig. 4
from Chi et al., 2008
|
heart contraction decreased process quality, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 2 ,
Fig. 3
from Chou et al., 2014
|
heart contraction decreased rate, abnormal
|
microgravity
|
Fig. 2
from Xie et al., 2019
|
heart contraction increased rate, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 2 ,
Fig. 3
from Chou et al., 2014
|
interrenal angiogenic sprout decreased length, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 3
from Chou et al., 2014
|
interrenal angiogenic sprout increased length, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 3
from Chou et al., 2014
|
interrenal gland animal organ morphogenesis process quality, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 2
from Chou et al., 2014
|
interrenal gland animal organ morphogenesis process quality, abnormal
|
chemical treatment: pharmaceutical
|
Fig. 2
from Chou et al., 2014
|
intersegmental vessel decreased amount, abnormal
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel decreased amount, abnormal
|
chemical treatment by environment: semaxanib
|
Fig. 6
from De Angelis et al., 2017
|
intersegmental vessel EGFP expression decreased distribution, abnormal
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel has fewer parts of type cell, abnormal
|
chemical treatment: semaxanib
|
Fig. 7
from Hassel et al., 2012
|
intersegmental vessel increased branchiness, abnormal
|
chemical treatment by environment: DAPT
|
Fig. 7
from Zhou et al., 2015
|
intersegmental vessel increased branchiness, abnormal
|
chemical treatment by environment: DAPT
|
Fig. 7
from Wang et al., 2016
|
intersegmental vessel malformed, abnormal
|
chemical treatment: semaxanib
|
Fig. 7
from Hassel et al., 2012
|
intersegmental vessel morphology, abnormal
|
chemical treatment by diet: sunitinib
|
Fig. 4
from Kanada et al., 2014
|
intersegmental vessel morphology, abnormal
|
chemical treatment: DAPT
|
Fig. 3,
Fig. 5
from Chappell et al., 2013
|
intersegmental vessel normal amount, normal
|
control
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel normal height, normal
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel normal height, normal
|
control
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel EGFP expression spatial pattern, abnormal
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel spatial pattern, normal
|
chemical treatment: SL-327
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel spatial pattern, normal
|
control
|
Fig. 7
from Chetty et al., 2020
|
intersegmental vessel angiogenesis increased process quality, abnormal
|
chemical treatment by environment: DAPT
|
Fig. 7
from Zhou et al., 2015
|
intersegmental vessel angiogenesis process quality, abnormal
|
chemical treatment: DAPT
|
Fig. 3,
Fig. 5
from Chappell et al., 2013
|
intersegmental vessel angiogenic sprout amount, normal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
intersegmental vessel angiogenic sprout decreased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib
|
Fig. 4
from Torraca et al., 2017
|
intersegmental vessel cell migration involved in sprouting angiogenesis arrested, abnormal
|
chemical treatment: semaxanib
|
Fig. 7
from Hassel et al., 2012
|
lateral dorsal aorta morphology, normal
|
heat exposure
|
Fig. 5
from Ton et al., 2018
|
liver morphology, normal
|
standard conditions
|
Fig. 5
from Sakaguchi et al., 2008
|
male organism decreased life span, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 1
from Carnovali et al., 2016
|
midbrain blood vasculature has fewer parts of type blood vessel, abnormal
|
chemical treatment: diacetylmonoxime
|
Fig. S13
from Chen et al., 2012
|
midbrain blood vasculature has fewer parts of type blood vessel, abnormal
|
chemical treatment: tricaine
|
Fig. S13
from Chen et al., 2012
|
midbrain blood vasculature morphology, abnormal
|
chemical treatment: diacetylmonoxime
|
Fig. S13
from Chen et al., 2012
|
midbrain blood vasculature morphology, abnormal
|
chemical treatment: tricaine
|
Fig. S13
from Chen et al., 2012
|
palatocerebral vein morphology, normal
|
heat exposure
|
Fig. 5
from Ton et al., 2018
|
pharyngeal vasculature decreased width, abnormal
|
chemical treatment: vatalanib
|
Fig. S9
from Fish et al., 2008
|
pharyngeal vasculature disorganized, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Porazzi et al., 2012
|
regenerating fin vasculature development decreased process quality, abnormal
|
amputation: caudal fin, chemical treatment: IWR-1-endo
|
Fig. 6
from Li et al., 2014
|
retina blood vessel broken, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 2
from Carnovali et al., 2016
|
retina blood vessel fragile, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 2
from Carnovali et al., 2016
|
retina blood vessel increased thickness, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 2
from Carnovali et al., 2016
|
retina blood vessel shape, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 2
from Carnovali et al., 2016
|
scale bglap expression decreased amount, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 4
from Carnovali et al., 2016
|
scale tnfsf11 expression decreased amount, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 4
from Carnovali et al., 2016
|
scale tnfrsf11b expression decreased amount, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 4
from Carnovali et al., 2016
|
scale decreased area, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 3
from Carnovali et al., 2016
|
scale morphology, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 3
from Carnovali et al., 2016
|
scale bone remodeling process quality, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 4
from Carnovali et al., 2016
|
scale bone resorption increased occurrence, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 3,
Fig. 4
from Carnovali et al., 2016
|
scale ossification involved in bone remodeling decreased occurrence, abnormal
|
chemical treatment by environment: D-glucose
|
Fig. 4
from Carnovali et al., 2016
|
sprouting angiogenesis increased occurrence, abnormal
|
chemical treatment: DAPT
|
Fig. 2
from Bussmann et al., 2011
|
subintestinal vein decreased length, abnormal
|
chemical treatment: IWR-1-endo
|
Fig. 5
from Li et al., 2014
|
subintestinal vein morphology, abnormal
|
chemical treatment: IWR-1-endo
|
Fig. 5
from Li et al., 2014
|
subintestinal venous plexus carcinoma present, abnormal
|
cancer xenotransplantation
|
Fig. 5
from Zhang et al., 2021
|
thyroid gland development decreased process quality, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Porazzi et al., 2012
|
thyroid primordium malformed, abnormal
|
chemical treatment: DAPT
|
Fig. 3
from Porazzi et al., 2012
|
trunk curved, abnormal
|
chemical treatment: DAPT
|
Fig. 5
from Ethell et al., 2014
|
trunk vasculature EGFP expression decreased amount, abnormal
|
chemical treatment by environment: pharmaceutical
|
Fig. 3
from Overman et al., 2017
|
trunk vasculature increased permeability, abnormal
|
chemical treatment by environment: lipopolysaccharide
|
Fig. 2
from Philip et al., 2017
|
trunk vasculature morphology, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 1 ,
Fig. 2 ,
Fig. 3 ,
Fig. 4
from Torraca et al., 2017
|
trunk vasculature morphology, ameliorated
|
bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib
|
Fig. 4
from Torraca et al., 2017
|
trunk vasculature response to bacterium process quality, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M, chemical treatment by environment: sunitinib
|
Fig. 4
from Torraca et al., 2017
|
vasculature agenesis, abnormal
|
chemical treatment by injection: methoxypoly(ethylene glycol), chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: curcumin
|
Fig. 8
from Gou et al., 2011
|
vasculature agenesis, abnormal
|
chemical treatment by injection: curcumin
|
Fig. 8
from Gou et al., 2011
|
vasculature morphology, abnormal
|
chemical treatment by injection: methoxypoly(ethylene glycol), chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: curcumin
|
Fig. 8
from Gou et al., 2011
|
vasculature morphology, abnormal
|
chemical treatment by injection: curcumin
|
Fig. 8
from Gou et al., 2011
|
ventral wall of dorsal aorta cell population proliferation decreased process quality, abnormal
|
chemical treatment: NS-398
|
Fig. 5
from Esain et al., 2015
|
ventral wall of dorsal aorta cell population proliferation increased process quality, abnormal
|
chemical treatment: cannabinoid receptor agonist
|
Fig. 5
from Esain et al., 2015
|
vertebral artery absent, abnormal
|
chemical treatment by environment: sunitinib
|
Fig. 3
from Matsuoka et al., 2017
|
vertebral artery absent, abnormal
|
chemical treatment by environment: vascular endothelial growth factor receptor antagonist
|
Fig. 3
from Matsuoka et al., 2017
|
vertebral artery absent, abnormal
|
chemical treatment by environment: LY294002
|
Fig. 3
from Matsuoka et al., 2017
|
whole organism kdrl expression amount, ameliorated
|
microgravity, chemical treatment: LY294002
|
Fig. 5
from Xie et al., 2019
|
whole organism fabp4a expression decreased amount, abnormal
|
chemical treatment by environment: SB 203580
|
Fig. S2
from Zhang et al., 2017
|
whole organism EGFP expression decreased amount, abnormal
|
chemical treatment by environment: pharmaceutical
|
Fig. 3
from Overman et al., 2017
|
whole organism fabp4a expression decreased amount, abnormal
|
chemical treatment by environment: sirolimus
|
Fig. S2
from Zhang et al., 2017
|
whole organism fabp4a expression decreased amount, abnormal
|
chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester
|
Fig. S2
from Zhang et al., 2017
|
whole organism kdrl expression decreased amount, abnormal
|
chemical treatment: LY294002
|
Fig. 6
from Xie et al., 2019
|
whole organism decreased size, abnormal
|
chemical treatment: DAPT
|
Fig. 5
from Ethell et al., 2014
|
whole organism cxcl11.1 expression increased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
whole organism vegfaa expression increased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
whole organism mmp9 expression increased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
whole organism cxcl12a expression increased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
whole organism tnfa expression increased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
whole organism kdrl expression increased amount, abnormal
|
microgravity
|
Fig. 3
from Xie et al., 2019
|
whole organism cxcl18b expression increased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
whole organism il1b expression increased amount, abnormal
|
bacterial treatment by injection: Mycobacterium marinum M
|
Fig. 4
from Torraca et al., 2017
|
whole organism length, normal
|
microgravity
|
Fig. 2
from Xie et al., 2019
|
whole organism neoplasm decreased size, ameliorated
|
chemical treatment by injection: gold nanoparticle, chemical treatment by injection: doxorubicin, cancer xenotransplantation
|
Fig. 4
from Ahn et al., 2015
|
whole organism nitric oxide increased amount, abnormal
|
microgravity
|
Fig. 4
from Xie et al., 2019
|